OncoMatch/Clinical Trials/NCT06881992
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Is NCT06881992 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Ersodetug for tumor hyperinsulinism (tumor hi).
Treatment: Ersodetug — The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: anti-hypoglycemic therapy
failed to achieve adequate control of hypoglycemia with usual SOC anti-hypoglycemic therapies
Cannot have received: investigational drug or device
Exception: if the treating physician and Medical Monitor consider no significant risk of drug-drug interaction and potential benefit outweighs the risk then the participant may be allowed
Treatment with an investigational drug or device within 30 days or 5 half-lives of the investigational drug (whichever is longer)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Investigative Site · Chicago, Illinois
- Investigative Site · Bethesda, Maryland
- Investigative Site · Boston, Massachusetts
- Investigative Site · Rochester, Minnesota
- Investigative Site · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify